Liberum Capital reissued their buy rating on shares of Huntsworth (LON:HNT) in a research note released on Friday morning, Stock Target Advisor reports.
Other research analysts have also recently issued reports about the stock. Peel Hunt reissued a buy rating on shares of Huntsworth in a report on Tuesday, October 8th. Peel Hunt reissued a buy rating and issued a GBX 135 ($1.76) price target on shares of Huntsworth in a report on Tuesday, October 1st. Finally, Berenberg Bank reissued a buy rating on shares of Huntsworth in a report on Thursday, October 10th. Five equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of Buy and a consensus price target of GBX 136 ($1.78).
Huntsworth stock traded up GBX 1.40 ($0.02) during trading hours on Friday, hitting GBX 88.40 ($1.16). The company had a trading volume of 27,073 shares, compared to its average volume of 1,010,000. The firm has a market cap of $327.17 million and a PE ratio of 27.63. The company has a debt-to-equity ratio of 73.94, a current ratio of 1.19 and a quick ratio of 1.10. Huntsworth has a one year low of GBX 76.60 ($1.00) and a one year high of GBX 116 ($1.52). The firm has a 50-day moving average of GBX 88.23 and a 200 day moving average of GBX 93.68.
Huntsworth plc, together with its subsidiaries, operates as a healthcare and communications company in the United Kingdom and rest of Europe, the United States, and internationally. The company operates through four divisions: Medical, Marketing, Immersive, and Communications. The Medical division provides scientific strategy and communications, publications planning and delivery, specialized medical writing, medical education, and payer and value communications services, as well as support services for internal medical teams.
Further Reading: What is the definition of arbitrage?
Receive News & Ratings for Huntsworth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Huntsworth and related companies with MarketBeat.com's FREE daily email newsletter.